Johnson & Johnson (JNJ)
248.61
+0.00 (0.00%)
NYSE · Last Trade: Oct 14th, 6:45 AM EDT
Detailed Quote
| Previous Close | 248.61 |
|---|---|
| Open | - |
| Bid | 250.00 |
| Ask | 250.58 |
| Day's Range | N/A - N/A |
| 52 Week Range | 184.66 - 281.07 |
| Volume | 12,053 |
| Market Cap | 653.52B |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | 5.360 (2.16%) |
| 1 Month Average Volume | 7,266,774 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.
Via The Motley Fool · October 13, 2026
Explore the top gainers and losers within the dow jones index in today's session.chartmill.com
Via Chartmill · October 13, 2026
These S&P500 stocks are moving in today's sessionchartmill.com
Via Chartmill · October 13, 2026
Johnson & Johnson beat earnings this morning. Then its stock price dropped.
Via The Motley Fool · October 13, 2026
Johnson & Johnson (NYSE:JNJ) Q3 2026: In-Line Results and Raised Guidance Offset by MedTech Weaknesschartmill.com
Via Chartmill · October 13, 2026
Johnson & Johnson (NYSE:JNJ): Dividend Quality Makes It a Durable Income Pickchartmill.com
Via Chartmill · October 10, 2026
Johnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook.
Via MarketBeat · October 13, 2026
Goldman Sachs gains on strong revenue while Johnson & Johnson stumbles on earnings miss, today, Oct. 13, 2026.
Via The Motley Fool · October 13, 2026
Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 worldwide sales of $25.4 billion, up 6% operationally from a year earlier, as growth in its Innovative Medicine business offset slower-than-expected performance in parts of MedTech. The company raised its full-year sales outlook and said it re
Via MarketBeat · October 13, 2026
Discover which dow jones stocks are making waves on Tuesday.chartmill.com
Via Chartmill · October 13, 2026
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Via Chartmill · October 13, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · October 13, 2026
Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighted on medical device sales.
Via Investor's Business Daily · October 13, 2026
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026.
By Johnson & Johnson · Via Business Wire · October 13, 2026
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026.
By Johnson & Johnson · Via Business Wire · October 13, 2026
These companies have a long history of dividend growth.
Via The Motley Fool · October 12, 2026
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.
Via The Motley Fool · October 12, 2026
You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
Via The Motley Fool · October 10, 2026
A 50-year dividend grower and a monthly income REIT; how J&J and Realty Income build lasting wealth for patient investors.
Via The Motley Fool · October 10, 2026
Friday's session: top gainers and losers in the dow jones indexchartmill.com
Via Chartmill · October 9, 2026
Top dow jones movers in Friday's sessionchartmill.com
Via Chartmill · October 9, 2026
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
Via The Motley Fool · October 8, 2026
These dow jones stocks are moving in today's sessionchartmill.com
Via Chartmill · October 8, 2026
Don't underestimate this healthcare giant.
Via The Motley Fool · October 8, 2026
TORRANCE, Calif., Oct. 8, 2026 (SEND2PRESS NEWSWIRE) -- DocMagic® announced today that Chief Operating Officer Lori Johnson has been named one of Mortgage Banker's 2026 Powerful Women of Mortgage Banking. The award recognizes women in mortgage banking who stand out as leaders by driving innovation, adapting to change and making a positive impact on their organizations, colleagues and the industry.
Via Send2Press · October 8, 2026